Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
Jonathan Strosberg(Moffitt Cancer Center), Matthew H. Kulke(Moffitt Cancer Center), Edward M. Wolin(University of Kentucky), Martyn Caplin(The Royal Free Hospital), Thomas Thevenet(Moffitt Cancer Center), David Bushnell(Cytel (United States)), Andrew Hendifar(Cedars-Sinai Medical Center), Inés Margalet(Dana-Farber Cancer Institute), Richard P. Baum(Hessische Hochschule für Polizei und Verwaltung), Maribel Lopera Sierra(Moffitt Cancer Center), Timothy J. Hobday(Mayo Clinic), Pamela L. Kunz(Dana-Farber Cancer Institute), Kjell Öberg(Uppsala University Hospital), Eric P. Krenning(Cyclotron (Netherlands)), Beth Chasen(The University of Texas MD Anderson Cancer Center), Philippe Ruszniewski(Inserm)
Cited by 388
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k